ALKS vs NERV
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance use disorders with proprietary long-acting injectable and extended-release technologies. NERV: Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on schizophrenia.
Side-by-side fundamentals
| Metric | ALKS | NERV | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $52.58 | $4.43 | |
| Market cap as of 2026-07-23 | $8.8B | $209M | |
| P/E as of 2026-07-23 | 57.68 | 144.94 | ALKS lower |
| PEG as of 2026-07-23 | 18.43 | n/a | |
| Net margin as of 2026-07-23 | +9.8% | +4.7% | ALKS higher |
| Gross margin as of 2026-07-23 | +86.6% | n/a | |
| Operating margin as of 2026-07-23 | +12.3% | +4.5% | ALKS higher |
| ROE as of 2026-07-23 | +8.8% | -169.6% | ALKS higher |
| ROA as of 2026-07-23 | +5.4% | -662.8% | ALKS higher |
| Debt / equity as of 2026-07-23 | 0.86 | 0.00 | NERV lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.9% | n/a | |
| Beta as of 2026-07-23 | 0.26 | -0.04 | |
| 1-year return as of 2026-07-22 close | +94.5% | +123.7% | NERV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.